摘要
目的 分析肝动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)与仑伐替尼在中晚期肝癌中联合应用的效果。方法 方便选取2020年3月—2023年3月寿光市人民医院收治的94例中晚期肝癌患者为研究对象,根据治疗方法不同分为对照组(47例)和观察组(47例)。对照组接受TACE治疗,观察组接受TACE联合仑伐替尼治疗,两组均随访1年。比较两组临床缓解情况、肿瘤标志物和血管生长因子水平及预后情况。结果 观察组客观缓解率为74.47%(35/47),高于对照组的53.19%(25/47),差异有统计学意义(χ^(2)=4.608,P<0.05)。治疗2个月后,观察组Ki-67抗原、增殖细胞核抗原水平分别为(18.52±7.11)pg/mL、(357.23±23.35)pg/mL,均低于对照组的(24.38±8.31)pg/mL和(392.06±26.18)pg/mL,差异有统计学意义(t=3.617、6.701,P均<0.05)。治疗2个月后,观察组血小板衍生生长因子、碱性成纤维细胞生长因子水平均低于对照组,差异有统计学意义(P均<0.05)。观察组总生存时间、疾病进展时间均长于对照组,差异有统计学意义(P均<0.05)。结论 TACE和仑伐替尼联合应用可降低中晚期肝癌患者Ki-67抗原等肿瘤标志物及血管生长因子水平,有利于肿瘤的控制及生存期的延长。
Objective To analyze the effect of combined application of transcatheter arterial chemoembolization(TACE)and lenvatinib in mid-late stage liver cancer.Methods A total of 94 patients with mid-late stage liver cancer admitted to Shouguang People's Hospital from March 2020 to March 2023 were conveniently selected as the research objects.According to different treatment methods,they were divided into control group(47 cases)and observation group(47 cases).The control group was treated with TACE,and the observation group was treated with TACE combined with lenvatinib.Both groups were followed up for 1 year.The clinical remission,tumor markers and vascular growth factor levels and prognosis were compared between the two groups.Results The objective remission rate of the observation group was 74.47%(35/47),which was higher than 53.19%(25/47)of the control group,and the difference was statistically significant(χ^(2)=4.608,P<0.05).After 2 months of treatment,the levels of Ki-67 antigen and proliferating cell nuclear antigen in the observation group were(18.52±7.11)pg/mL and(357.23±23.35)pg/mL,respectively,which were lower than those in the control group(24.38±8.31)pg/mL and(392.06±26.18)pg/mL,the differences were statistically significant(t=3.617,6.701,both P<0.05).After 2 months of treatment,the levels of platelet-derived growth factor and basic fibroblast growth factor in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).The total survival time and disease progression time of the observation group were longer than those of the control group,and the differences were statistically significant(both P<0.05).Conclusion The combination of TACE and lenvatinib can reduce the levels of tumor markers such as Ki-67 antigen and vascular growth factor in patients with mid-late stage liver cancer,which is beneficial to tumor control and prolong survival.
作者
吴福勇
WU Fuyong(Tumor departmentⅡ,Shouguang People's Hospital,Shouguang 262700,Shandong,China)
出处
《中外医疗》
2024年第24期51-54,共4页
China & Foreign Medical Treatment
关键词
经导管动脉栓塞化疗
仑伐替尼
肝癌
中晚期
增殖细胞核抗原
Transcatheter arterial chemoembolization
Lenvatinib
Liver carcer
Mid-late stage
Proliferating cell nuclear antigen
